Alpha Tau (DRTS) director discloses initial shares, RSUs and options
Rhea-AI Filing Summary
Alpha Tau Medical Ltd. director Nadav Kidron filed an initial statement of beneficial ownership, detailing his current equity position in the company. He directly holds 2,986 ordinary shares, along with restricted share units (RSUs) covering 7,767 and 4,680 ordinary shares. The 7,767 RSUs vest in equal monthly installments over three years starting May 12, 2025, subject to continued service, while the 4,680 RSUs vest in full on the earlier of one year from March 9, 2026 or the next annual general meeting. Kidron also holds options over 35,554 ordinary shares at an exercise price of $2.79 expiring in 2035, which vest monthly over three years from May 12, 2025, and options over 15,527 shares at $6.41 expiring in 2036, vesting in full on the earlier of one year from March 9, 2026 or the next annual general meeting.
Positive
- None.
Negative
- None.
FAQ
What does the Form 3 filing by Nadav Kidron for Alpha Tau Medical (DRTS) show?
How many ordinary shares does Nadav Kidron directly hold in Alpha Tau Medical (DRTS)?
What restricted share units (RSUs) does Nadav Kidron report for Alpha Tau Medical (DRTS)?
What stock options does Nadav Kidron hold in Alpha Tau Medical (DRTS)?
Are Nadav Kidron’s Alpha Tau Medical (DRTS) equity awards subject to vesting conditions?
Does the Form 3 for Alpha Tau Medical (DRTS) show any recent insider stock purchases or sales?